Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits

Tijana Drobnjak¹
Hamutal Meiri²,³
Maurizio Mandalá⁴
Berthold Huppertz⁵
Sveinbjörn Gizurarson¹
¹Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland; ²Hy Laboratories, Rehovot, Israel; ³TeleMarpe Ltd., Tel Aviv, Israel; ⁴Department of Biology, Ecology and Earth Sciences, University of Calabria, Rende, Italy; ⁵Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria

Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia.

Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model.

Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p<0.01). PP13 elimination half-life was also found to be different between the groups (p<0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%.

Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated.

Keywords: PP13, ELISA, PK, eNOS, prostaglandin, preeclampsia

Introduction

Human placental protein 13 (PP13) is a member of placently expressed proteins and of β-galactoside-binding proteins or galectins.¹ ² PP13 was first isolated in 1983 by Bohn from human placenta³ and is predominantly expressed in this organ;⁴ however, Than et al have reported its presence in rare tumors of fetal spleen and liver tissues as well.¹ Several studies in humans have shown that low PP13 levels in maternal serum early in pregnancy are associated with the subsequent development of preeclampsia,⁵ ⁶ an obstetrical complication affecting around 2%–5% of all pregnancies and one of the leading causes of maternal and perinatal morbidity and mortality.⁷ ⁸ Preeclampsia is a disorder characterized by a constellation of signs and symptoms, eminently new onset of hypertension and proteinuria developed from the midst of pregnancy in previously normotensive women with no such symptoms.⁷ ⁸ Later in life, the disorder can increase the frequency of developing cardiovascular diseases in women with a history of preeclampsia.⁹ ¹⁰ Earlier meta-analyses of PP13 across various studies in humans have described a significant decrease in circulating concentrations in early pregnancy in those women developing preeclampsia later in pregnancy.¹ This decrease might be directly related to the severity of the disorder. Other parameters like ethnic origin, obesity, blood groups, and genetic polymorphism of the protein’s primary sequence play a major role in the severity of preeclampsia and especially among women of African origin.⁶ ¹¹–¹⁴
PP13 is secreted from the placental syncytiotrophoblast, and as galectin 13, it shows structural homologies to other members of the galectin family.\(^{15}\) It has high affinity for sugar residues and is implied to be involved in conferring immunotolerance of the mother at the site of trophoblast invasion during uterine artery remodeling in early pregnancy in order to enable deep placentation.\(^{16–19}\)

Studies performed in rats have shown that PP13 decreases blood pressure,\(^{20}\) and it has been shown to induce vasodilatation of resistance arteries through endothelial signaling involving the pathways of endothelial nitric oxide synthase (eNOS) and prostaglandin.\(^{21}\) In rats, PP13 administration results in larger pups and heavier placentas due to a possible increase in blood flow and oxygen supply to the uterine vasculature in pregnancy. It has been suggested that PP13 replenishing in pregnancies with low maternal serum level may assist in preventing preeclampsia.\(^{5,12,22}\) Thus, it is important to understand the availability of PP13 administrated externally. The aim of the current study was to determine the kinetic disposition and bioavailability of PP13 in serum after intravenous (IV) and subcutaneous (SC) administration of the protein in healthy rabbits.

Materials and methods

Animals and ethics approval

Twelve female nonpregnant New Zealand White (NZW) rabbits were purchased from Envigo (Huntington, UK) and housed at the laboratory animal care facility at the University of Iceland (Reykjavik, Iceland).

The NZW rabbits, each weighing on average 3.9±0.3 kg, were caged in groups of three with access to food and water ad libitum and maintained on a 12/12 h light/dark cycle.

The study was approved by the Icelandic Animal Ethic Committee (study number: 2015-09-02) and carried out according to the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were undertaken according to the “3R principles” (www.nc3rs.org.uk) to reduce the number of animals used in the study and optimize experimental protocols for obtaining maximum data from each tested animal.

Placental protein 13

Recombinant PP13 without the histidine tag was prepared by expressing the recombinant wild-type PP13 construct in *Escherichia coli*, harvesting, and purification as was already described,\(^{23}\) and its DNA sequence was verified by Sanger sequencing (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC431765/). The molecular weight and the purity of the protein were verified by sodium dodecyl sulphate polyacrylamide gel electrophoresis, high performance liquid chromatography, and immunoblots with PP13-specific monoclonal antibodies. The concentration was determined using a PP13 enzyme-linked immunosorbent assay (ELISA) kit as previously described.\(^{23}\)

Experimental procedure

The animals were divided into four experimental groups (n=6/group). Each animal was assigned to one group, allowed to rest for a week, and then allocated to a different experimental group. Three groups received IV injection (1.3, 2.6, or 12.8 ng/kg) of PP13 that was administered into the right marginal ear vein. The fourth group received SC injection (12.8 ng/kg), administered under the skin, at the neck area on the back.

PP13 was diluted in 0.9% saline solution at 5, 10, and 50 ng/mL, corresponding to concentrations of 1.3, 2.6, and 12.8 ng/kg, respectively, and was administered as a single IV injection or by SC route (only 12.8 ng/kg).

A blood control sample of ~1 mL was collected from the marginal vein of the left ear (opposite to the administration side) of each animal and stored into serum vacutainer tubes. The blood was collected prior to protein administration (T\(_0\)) and also at a time series of 10, 30, 60, and 90 min and 2, 4, 6, and 24 h after PP13 administration.

Blood samples were centrifuged within 2 h after collection, and the separated serum was kept frozen at −80°C until further analysis. The storage at −80°C does not have any impact on PP13 protein stability.\(^{24}\)

Analytical assay

PP13 in the serum samples was determined by a commercially available ELISA kit from Cusabio (Wuhan, China; category number: CSB-E12733h). All the samples were analyzed in duplicates. The working range of the assay is from 2.5 to 1,000 pg/mL. Calibration curves had a regression coefficient at R\(^2\)=0.99. Intraassay precision and interassay precision had a coefficient of variance of 10% and 11%, respectively. Interassay precision was determined by measuring standard samples on three separate days. The calibration curves were fitted with a four-parameter logistic equation.

Pharmacokinetics and statistical analysis

PP13 serum concentrations of each animal were analyzed over time using GraphPad Prism (GraphPad Software, San Diego, CA, USA). To describe the pharmacokinetics of PP13 after both IV and SC administration, a two-compartment model with linear elimination was used. Data were collected and calculated in Microsoft Excel, using standard pharmacokinetic equations and simulations. All statistics were performed using GraphPad InStat on Prism (GraphPad Software).
The absorption half-life ($t_{1/2,\text{abs}}$), elimination half-life ($t_{1/2}$), elimination constant ($\beta$), distribution rate constant ($\alpha$), and total body clearance ($Cl_{\text{tot}}$) were calculated. Areas under the serum concentration–time curves for both IV (area under the curve [AUC]$_{IV,0-\infty}$) and SC (AUC$_{SC,0-\infty}$) injections were calculated by the method of trapezoids and presented as pg PP13 per h/mL (pg·h/mL). Peak serum PP13 concentration ($C_{\text{max}}$) and time to reach $C_{\text{max}}$ ($t_{\text{max}}$) were determined directly from the individual serum concentration–time curves for the SC administration. Also, the bioavailability of PP13 from the individual serum concentration–time curves for both IV (area under the full curve [AUC]$_{IV}$) were calculated. All results are presented as mean ± SD. Harmonic means were calculated for $t_{1/2}$ and AUC and presented as mean ± standard error (SE).

Mann–Whitney $U$ test was used to evaluate the statistical significance of the differences in $t_{1/2}$. The AUCs were compared using the independent samples $t$-test. $p<0.05$ was considered statistically significant for all tests. Student’s $t$-test was used for data comparison between groups. All values are presented as mean ± SD, but $t_{1/2}$ and AUC$_{0-\infty}$ are presented as harmonic mean ± SE.

**Results**

**IV administration**

Serum concentration–time profiles of PP13, following single-dose IV administration of 1.3, 2.6, and 12.8 ng/kg, are shown in Figure 1. The two-compartment model was found to fit best for the majority of animals and used to calculate the pharmacokinetic parameters. The calculated values for AUC were 315±47, 495±28, and 1,360±82 pg·h/mL for 1.3, 2.6, and 12.8 ng/kg, respectively. When corrected for the dose given, AUC was equivalent to 246, 193, and 106 pg·h/mL, showing that there is a drastic significant reduction in AUC with increased dose ($p=0.004$). Likewise, when volume of distribution (Vd) was compared, there was a significant difference in the value between the lowest and the highest dose ($p<0.001$). These findings suggest that PP13 binding reached saturation, and thus, it appears that the protein might follow nonlinear pharmacokinetics.

The half-life following IV injection was calculated to be 5.16±0.97, 4.42±0.77, and 4.60±0.09 h for these three doses, respectively. The clearance for these three doses was found to be 14.0±1.9, 20.3±3.5, and 33.5±2.6 mL/kg/h, respectively.

**SC administration**

Mean serum concentration–time profiles of PP13 following SC administration of a single dose (12.8 ng/kg), in comparison with IV administration, are presented in Figure 2. The corresponding pharmacokinetic parameters were obtained by the two-compartmental analysis. Following SC administration of a single dose at 12.8 ng/kg, the $t_{1/2}$, $C_{\text{max}}$, AUC, and $Cl$ were 11.4±1.0 h, 4.5±0.4 h, 130±11 pg/mL, 805±62 pg·h/mL, and 60.4±12.5 mL/kg/h, respectively. Based on the equivalent IV dose, the bioavailability ($F$) was calculated to be 57.1±3.2%.

When the study was performed, all rabbits were clinically healthy and no side effects were observed after the administration of PP13 at any concentration, either after IV (1.3, 2.6, and 12.8 ng/kg) or after SC (12.8 ng/kg) injections. SC administration was less invasive and easier to manage.
Comparison of parameters between the routes of administration

The half-life ($t_{1/2}$) was significantly different between the IV and SC groups receiving the equivalent dose ($p=0.002$). AUC and Cl$_{int}$ were also found to be significantly different ($p<0.001$). After the SC administration, PP13 reached the $C_{max}$ at 90 min, and the bioavailability was calculated to be about 57%, compared with the same dose administered intravenously. The protein was almost completely eliminated from the blood during the next 24 h in all groups.

The comparison between the different doses (1.3 and 12.8 ng/kg) for IV administration revealed a significant difference between AUC/dose ($p=0.004$) and Vd ($p<0.001$).

The pharmacokinetic parameters of PP13 for both IV and SC administration routes are presented in Table 1.

Discussion

Rabbits are among the most commonly used animals in preclinical drug development, and it is of utmost importance to understand the differences and similarities in the pharmacokinetic behavior of drug molecules for proper interpretation and integration in the development process for therapies. Therefore, the current study was designed to investigate the pharmacokinetic profile of PP13 in rabbits via two administration routes, and to our knowledge, this study is the first report describing the pharmacokinetics of PP13.

In our previous study conducted in rats, we observed that PP13 was a highly active vasodilator, acting via the vascular endothelium through both eNOS and prostaglandin signaling pathways. We have also observed that intraperitoneal delivery of PP13 from osmotic pumps in pregnant rats reduced blood pressure. The effect of PP13 in both rodents and lagomorphs is considered pharmacological, since both species lack the LGALS13 gene encoding for the protein, which is specific to primates.

The absorption kinetics of proteins following SC administration and the distribution of proteins to various tissues are a complex interaction of multiple processes, including absorption by lymphatic capillaries, interstitial transport, specific and nonspecific binding, and presystemic degradation. The structure of the skin as well as the SC space might have an impact on drug absorption as well.

In this study, we observed a relatively short half-life of the protein in all groups. These findings might indicate a rapid elimination of PP13. The rapid elimination could be accounted for by antigen binding to red blood cells and vascular endothelial blood vessels, or by tight binding of PP13 (a galectin) to putative tissue receptors (eg, sugar residues of various proteins).

The dose-corrected pharmacokinetic difference between 1.3 and 12.8 ng/kg dose groups (IV), for both AUC and Vd, presented in Table 1, was unusual and may be explained by the overall effect that the protein might have on blood pressure, endothelium, and selected arteries and veins.

### Table 1 Pharmacokinetic parameters for both administration routes based on individual data

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group 1 (1.3 ng/kg IV)</th>
<th>Group 2 (2.6 ng/kg IV)</th>
<th>Group 3 (12.8 ng/kg IV)</th>
<th>Group 4 (12.8 ng/kg SC)</th>
<th>p-value (Group 3 vs Group 4)</th>
<th>p-value (IV groups)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$t_{1/2}$ (half-life) (h)</td>
<td>5.16±0.97</td>
<td>4.42±0.77</td>
<td>4.60±0.09</td>
<td>11.40±1.03</td>
<td>0.002**</td>
<td>0.29</td>
</tr>
<tr>
<td>$r_{1/2}$ (h)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>4.50</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>$k_e$ (h$^{-1}$)</td>
<td>0.15±0.07</td>
<td>0.16±0.03</td>
<td>0.15±0.01</td>
<td>0.06±0.02</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>$k_{int}$ (h$^{-1}$)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>1.78±0.34</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>$\alpha$ (h$^{-1}$)</td>
<td>0.36±0.14</td>
<td>0.50±0.13</td>
<td>0.60±0.23</td>
<td>0.24±0.09</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>$\beta$ (h$^{-1}$)</td>
<td>0.09±0.03</td>
<td>0.13±0.04</td>
<td>0.04±0.03</td>
<td>0.14±0.04</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>1.84±0.19</td>
<td>1.23±0.17</td>
<td>0.62±0.18</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Vd$_{int}$ (ml/kg)</td>
<td>25.8±0.0</td>
<td>25.7±0.0</td>
<td>14.3±0.7</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>AUC$_{int}$ (pg h/ml)$^1$</td>
<td>315±47</td>
<td>495±28</td>
<td>1.36±82</td>
<td>805±62</td>
<td>0.001**</td>
<td>N/A</td>
</tr>
<tr>
<td>Cl$_{int}$ (ml/kg/h)</td>
<td>14.0±1.9</td>
<td>20.3±3.5</td>
<td>33.5±2.6</td>
<td>60.4±12.5</td>
<td>0.001***</td>
<td>0.001***</td>
</tr>
<tr>
<td>$C_{max}$ (pg/mL)</td>
<td>58.4±10.9</td>
<td>78.9±9.6</td>
<td>217.0±19.3</td>
<td>130.0±11.4</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>$t_{max}$ (min)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>90</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Vd (L)</td>
<td>110±13</td>
<td>132±20</td>
<td>228±33</td>
<td>1.126±498</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Vd$_{AUC}$ (L)</td>
<td>3.05±0.74</td>
<td>3.89±0.93</td>
<td>6.40±1.94</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>AUC/dose (h/mL)$^1$</td>
<td>0.07±0.02</td>
<td>0.05±0.01</td>
<td>0.03±0.004</td>
<td>0.02±0.003</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>F$^2$</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>57.1±3.2</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Notes: Each group contained 6 rabbits. Harmonic mean. $p$-value was calculated between two groups where the same concentration of the drug was given. $^1$$^1$$p$$≤$$0.001$.

Abbreviations: AUC, area under the concentration–time curve; AUC/dose, AUC corrected for dose; Cl$_{int}$, total body clearance; $C_{max}$, maximal plasma concentration; F, bioavailability; IV, intravenous; $k_{int}$, absorption rate constant; $k_e$, elimination constant; MRT, mean residence time; N/A, not applicable; SC, subcutaneous; $t_{1/2}$, absorption half-life; $t_{max}$, half-life; $t_{max}$, time to maximum concentration; Vd, volume of distribution; Vd$_{AUC}$, Vd corrected for AUC; Vd$_{int}$, volume of distribution at steady state; $\alpha$, distribution rate constant; $\beta$, elimination rate constant.
The specific binding site for PP13 has not yet been defined, although, similar to most galectins, PP13 might bind to sugar residues, such as N-acetyl-lactosamine and lactose. Studies from affinity chromatography and mass spectroscopy identified high-affinity binding of PP13 to annexin II and β-γ-actin. Annexin II is expressed on both activated and resting endothelial cells, and PP13 mainly works on the endothelial layer of arteries. In addition, the binding can be to sugar residues of the B and AB antigens of the ABO blood groups (oligosaccharides conjugated to cell-surface glycolipids and glycoproteins), as was shown by Than et al. Such interactions are potentially important regulators for the availability of free PP13 in the blood circulation and have been found to influence the prediction of the risk to develop preeclampsia and should also be considered for PP13 bioavailability in rabbits, which also carry different blood groups.

In a study by Huppertz et al., in which the serum levels of PP13 were measured throughout pregnancy, the authors reported a 1.4- to 2-fold increase in the blood levels of PP13 in normal pregnancies between the first and third trimesters. The starting concentrations were around 200 pg/mL in early pregnancy (gestational weeks 5–8) reaching about 400 pg/mL in late pregnancy (gestational weeks 36–40). In normal pregnancy, maternal blood PP13 level almost completely disappears within few weeks after delivery and placental removal. However, women who later developed preeclampsia had serum levels under 50 pg/mL in the first trimester, followed by a 7- to 15-fold increase of PP13 by week 36. PP13 serum levels in these women vanished very slowly after delivery and could be determined for 5–6 weeks postpartum and occasionally longer. A recent study by Madar-Sharipo et al. has shown that combining the presence of the A/A genotype in the −98 site of the PP13 promoter with obesity, African (black) origin, and history of preeclampsia significantly increases the accuracy of predicting the risk of preeclampsia. The determination of low serum levels of PP13 in early pregnancy contributes to the prediction of preeclampsia as well. Therefore, it is tempting to suggest the possible utility of PP13 as a biomarker for predicting the disorder.

Immunostaining for PP13 in human placenta showed that it is found in the cytoplasm and brush border membrane of the syncytiotrophoblast and its microparticles (STBMs) that are subsequently shed into the maternal circulation along with their PP13 content.

Based on this study and previous findings, we hypothesize that an elevated amount of PP13 that is released from the placenta into the maternal circulation via STBMs or as free molecules circulates in the maternal blood where it may bind to blood vessels, red blood cells, and potentially to other maternal organs. Hence, the apparent amount of free PP13 that is determined in the blood is just a fraction of the total PP13 released from the placenta.

We propose that the free PP13 determined in the rabbit blood samples may vary due to factors such as 1) high-affinity binding to the AB and B antigens of the ABO blood groups; 2) specific binding to endothelial binding sites related to the eNOS and prostaglandin pathways; and 3) blood vessel vasodilation and hypotension induced by PP13, which may also influence 4) the peripheral blood return and potentially also the cardiac output. The latter is extremely important when looking at uterine arteries where it has been shown that the Doppler pulsatility index (arterial stiffness and resistance) is higher in patients who subsequently developed preeclampsia. It was also shown that combining low PP13 with high uterine arteries Doppler pulsatility index can accurately predict the risk to develop preeclampsia.

If PP13 release from the placental STBMs is considered to be constant in early pregnancy, using a theoretical concentration at steady state \( \left( C_{ss} \right) \) of 300 pg/mL (corresponding to the average serum levels in normal pregnancies), and data used in this study for allometric scaling between species, then the PP13 dose that is released into the circulation is 1.07 pg/h in unaffected pregnancies. When correcting the serum concentration of women who are at risk for developing preeclampsia, the loading IV dose would be around 50 pg/kg of PP13 and 90 pg/kg if given through SC route. To maintain the correct serum concentration of PP13 throughout pregnancy, based on our data, the dose required would be 10 pg/kg if given daily through IV route or 20 pg/kg if given through SC route.

This study has limitations since it was conducted in nonpregnant rabbits, and in addition, as mentioned previously, the LGALS13 gene is expressed in primates but not in rabbits. Therefore, the overall antigen binding of PP13 might differ between species. Galectins can undergo pinocytosis into exosomes that are being released from the placenta. However, this transfer has not yet been elucidated for PP13 outside the placenta. This could be another limitation of our study.

When it comes to the clinical setting of the protein, as described previously, IV administration is unlikely to be used; however, understanding the pharmacokinetic behavior of the drug after IV bolus administration is important. Dose-dependent parameters differ between IV doses. It is suggested that the dose-dependent pharmacokinetics might be explained by the effect PP13 has on the vascular system,
as reported in our previous studies. Thus, when it comes to administration of PP13 to pregnant women, the duration of the drug administration and total volume remain to be tested in greater detail.

Finally, the protein absorption by the lymphatic capillaries was not evaluated here and might be considered as another limiting factor.

**Conclusion**

Based on our findings, we hypothesize that the circulating blood levels of PP13 determined by various methods represent only a fraction of what is secreted by the placenta. The rest remains bound to red blood cells, the endothelial layer, and other maternal organs. The study provides important information regarding the basic pharmacokinetic parameters, where some factors were found to be affected by increasing dosage. To estimate the overall systemic distribution of PP13, additional studies are required. In addition, since rabbits are not identical to humans, further studies in humans are needed.

**Acknowledgments**

The authors thank Hy Laboratories for providing PP13 to this study through support provided by the European Union through the ASPRE project (#601852). This study was mainly sponsored by Hananjaehf and the Icelandic Research Fund (Rannis; grant number 163403-052).

**Disclosure**

Hamutal Meiri and Sveinbjörn Gizurarson hold a patent for the potential therapeutic use of PP13 in pregnancy complications. Hamutal Meiri is the CEO and Chairman of TeleMarpe Ltd. and is a consultant of Hy Laboratories. The authors report no other conflicts of interest in this work.

**References**


